Trial
NCT01940900
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Ophthotech Corporation
Collaborators
—
Condition
Age-Related Macular Degeneration
Intervention
E10030
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-30